PureTech Health (PRTC)
(Delayed Data from NSDQ)
$28.68 USD
+0.17 (0.60%)
Updated May 16, 2024 12:04 PM ET
After-Market: $29.25 +0.57 (1.98%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRTC 28.68 +0.17(0.60%)
Will PRTC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PRTC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRTC
PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround
PRTC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PRTC
PureTech Entity Begins Landmark C. difficile Trial
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
PureTech-founded,Vedanta, enrollls 1st patient in RESTORATiVE303 sudy of VE303
IN BRIEF: PureTech Health launches USD100 million buyback programme
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share